Merck KGaA Profit Beats Estimates on Cost-Cutting
May 14 (Bloomberg) -- Merck KGaA, the German maker of cancer drug Erbitux, said first-quarter profit rose on higher-than-expected savings from a reorganization program, and forecast it will achieve 2014 targets a year ahead of schedule. Mark Barton reports on Bloomberg Television's "Countdown." (Source: Bloomberg)
Most Recent Videos
Honeywell CEO Cote: Why Free Trade Is Good for U.S.
20:51 - David Cote, chairman and chief executive officer at Honeywell, explains why trade is important to his company and the U.S. economy, the populist backlash against free trade in America, and what he is looking for in the next U.S. president. He speaks on "Bloomberg ‹GO›." (Source: Bloomberg)